Searching for clues: can we predict who will beat bile duct cancer?
NCT ID NCT06648057
Summary
This study aims to understand why some patients with advanced bile duct cancer respond better than others to a specific two-drug treatment (lenvatinib plus pembrolizumab). Researchers will follow 100 patients receiving this treatment in real-world clinics to see how well it works and how safe it is. The main goal is to analyze blood and tumor samples to find biological markers that can predict which patients are most likely to benefit from this therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.